UPDATE: Morgan Stanley Initiates Cubist Pharmaceuticals at Overweight on Strategic Positioning

Loading...
Loading...
Morgan Stanley initiated coverage on Cubist Pharmaceuticals
CBST
with an Overweight rating and a %68 price target. Morgan Stanley commented, "We believe the Street is currently undervaluing Cubist's focused approach to hospital based drugs – a strategy that we find attractive based on a) a more complex commercial process which tends to yield less competition, b) a large unmet need which allows volume and pricing power, and c) the potential for a focused, well leveraged commercial infrastructure." Cubist Pharmaceuticals closed at $48.48 on Wednesday.
Posted In: Analyst ColorPrice TargetInitiationIntraday UpdateAnalyst RatingsMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...